Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel’s foremost medical research center – the Hadassah University Hospital ("Hadassah").
The HBL traded stock, as a unique investment vehicle, provides investment exposure to a select portfolio of 9 biotech companies - all based on inventions developed and owned by Hadassah. The companies operate in the fields of Oncology, Regenerative Medicine and Inflammatory Disease.
HBL focuses on funding the execution of Phase I and preparation for Phase II by the portfolio companies. Success in either of these stages can multiply the valuation of each company up to 10X for each milestone. |
